In states with medical cannabis laws, Medicare prescriptions for pain, nausea, anxiety, depression, seizures, and sleep dropped significantly — saving $165.2 million per year and demonstrating population-level drug substitution.
Policymakers, healthcare economists, medical cannabis patients, pharmaceutical industry analysts.
$165.2 million — annual Medicare savings from reduced prescriptions in states with medical cannabis laws
The Backstory
Bachhuber showed that states with medical cannabis laws had fewer opioid deaths. But deaths are a lagging indicator — the endpoint of a long chain of prescribing, dependence, dose escalation, and overdose. Ashley and David Bradford asked a simpler, earlier question: when states legalize medical cannabis, do doctors write fewer prescriptions?
They looked at the place where prescribing is most precisely tracked: Medicare Part D, the federal prescription drug benefit covering tens of millions of Americans. And they found something the pharmaceutical industry didn't want to see: in every drug category for which cannabis could serve as an alternative, prescriptions dropped — and the savings were measured in hundreds of millions of dollars.
The Analysis
The Bradfords analyzed Medicare Part D prescribing data from 2010 to 2013, comparing states that had implemented medical cannabis laws to those that hadn't. They focused specifically on drug categories where cannabis has a plausible therapeutic alternative: pain, nausea, anxiety, depression, psychosis, seizures, sleep disorders, and spasticity.
Medicare Prescribing
When Cannabis Is Legal, Patients Use Fewer Prescription Drugs
$165.2M
Annual Medicare savings
in 2013 from reduced prescriptions
1,826
Fewer daily opioid doses
per physician per year in dispensary states
Significant
Reductions across categories
pain, nausea, anxiety, seizure, sleep
9
Drug categories analyzed
where cannabis is a clinical alternative
Bradford & Bradford (2016), Health Affairs 35(7):1230-1236
The reductions weren't limited to opioids. In states with medical cannabis laws, prescriptions decreased for:
- Pain medications (including opioids) — the largest reduction
- Anti-nausea medications — consistent with cannabis's well-documented antiemetic properties
- Anti-anxiety medications — suggesting patients may be substituting cannabis for benzodiazepines
- Antidepressants — a more surprising finding
- Anti-seizure medications — consistent with the CBD-epilepsy evidence
- Sleep medications — consistent with cannabis's sedative properties
Healthcare Economics
Following the Money
The finding
When patients have legal access to cannabis, they fill fewer prescriptions for drugs that cannabis can replace — measurable in Medicare Part D claims data.
The magnitude
$165.2 million per year in Medicare savings alone. This doesn't count savings in other insurance programs, out-of-pocket costs, or the reduced burden of prescription drug side effects.
The mechanism
Patients aren't told to stop their prescriptions — they're choosing to substitute cannabis. This is patient-driven substitution, happening in the exam room and at the pharmacy counter.
The implication
Legal cannabis doesn't just affect drug policy — it affects the pharmaceutical industry's revenue. Every prescription replaced by cannabis is revenue lost by a drug manufacturer.
Bradford & Bradford (2016)
Why This Study Matters More Than The Numbers Suggest
The Bradfords' analysis was important not just for the dollar figures, but for what it revealed about how medicine is practiced. When patients have access to cannabis, they and their doctors make different choices. The prescribing changes weren't random — they tracked exactly the conditions where cannabis has therapeutic plausibility. This is biologially coherent substitution, not noise.
The study also had a clever natural experiment built in: states with active dispensaries (where cannabis was actually accessible) showed larger prescribing reductions than states with laws but no dispensaries. This dose-response relationship — more access, more substitution — strengthens the causal argument.
The Follow-Up
The Bradfords published a companion study (2017) using the same approach with Medicaid data and found similar results: states with medical cannabis laws showed significant reductions in Medicaid prescriptions for pain, depression, nausea, anxiety, and seizures. A subsequent study (2018) examining Medicare Part D specifically for opioids found that states with medical cannabis laws had 2.21 million fewer daily opioid doses prescribed per year.
These replications across different datasets, insurance programs, and time periods strengthened the original finding considerably.
Myth vs. Reality
Cannabis legalization just adds another drug to the mix — it doesn't reduce other drug use.
Multiple analyses of actual prescribing data show that legal cannabis access is associated with measurable reductions in prescriptions for opioids, anti-anxiety medications, antidepressants, sleep aids, anti-nausea drugs, and seizure medications. Patients are substituting, not just adding.
The Evidence
Bradford & Bradford (2016) found $165.2M in annual Medicare savings. Subsequent analyses of Medicaid, Medicare Part D, and commercial insurance showed similar patterns. States with dispensaries showed larger effects than states with laws but no access points.
Bradford & Bradford (2016, 2017, 2018)
The Limitations
This study shares the ecological design limitations of Bachhuber's work — it compares states, not individuals. The reductions could reflect other policy changes that correlate with cannabis legalization. And the study can't determine whether the prescribing reductions improved or worsened patient outcomes. Fewer opioid prescriptions is probably good; fewer antidepressant prescriptions is less clearly positive, since trading SSRIs for cannabis requires careful consideration.
The $165.2 million figure sounds large but represents a small fraction of total Medicare Part D spending (~$100 billion per year). The clinical significance for individual patients may be more meaningful than the aggregate economic impact.
Related Research
Cannabis and Prescription Drug Substitution
From population prescribing data to individual patient decisions.
Medical marijuana laws and opioid mortality
Bachhuber et al. (2014)
The companion finding: states with cannabis laws had fewer opioid deaths. Bradford showed the prescribing mechanism behind it.
Patients prefer cannabis over opioids
Boehnke et al. (2016)
The individual-level perspective: 64% of medical cannabis patients reduced opioid use. Bradford's Medicare data shows the same pattern at population scale.
Cannabis as a substitute for prescription drugs
Corroon et al. (2017)
Patient survey data: 46% used cannabis as a prescription drug substitute — opioids, antidepressants, and sleep aids most commonly replaced.
How much money does cannabis save Medicare?
Bradford & Bradford estimated $165.2 million per year in 2013 — from reduced prescriptions in drug categories where cannabis is a clinical alternative. This is a conservative estimate: it doesn't include savings from other insurance programs, reduced hospitalization for drug side effects, or indirect economic benefits from patients functioning better on cannabis than on their previous medications.
Which prescriptions decrease when cannabis is legal?
Prescriptions for pain medications (including opioids), anti-nausea drugs, anti-anxiety medications, antidepressants, seizure medications, and sleep aids all showed statistically significant reductions in states with medical cannabis laws. The reductions were largest in states with active dispensaries.
Is it safe to replace prescriptions with cannabis?
That depends entirely on which medication and why. Replacing opioids with cannabis for chronic pain is generally considered a net positive given the comparative safety profiles. Replacing anti-seizure medication with cannabis should only be done under medical supervision. Replacing antidepressants with cannabis is controversial — see our guide on SSRIs and cannabis. Never stop a prescription medication without consulting your prescriber.
What the researchers found
Medical cannabis laws associated with significant reductions in Medicare Part D prescriptions for opioids, anti-nausea, anti-anxiety, antidepressant, seizure, and sleep medications. Estimated annual savings: $165.2 million (2013). States with dispensaries showed larger reductions.
Why it matters
Connected cannabis policy to healthcare economics. Showed that legal cannabis access produces measurable shifts in prescribing patterns — patients substitute cannabis for prescription drugs across multiple categories.
How the study worked
Retrospective analysis of Medicare Part D prescription claims data across all states, 2010-2013. Compared prescribing patterns in states with and without medical cannabis laws. Focused on 9 drug categories where cannabis is a plausible alternative.
What this study cannot tell us
Ecological design. Cannot determine whether prescribing reductions improved patient outcomes. Fewer antidepressant prescriptions may not be positive. Small fraction of total Medicare spending.
How to read the evidence
Ecological analysis of actual prescribing data — replicated across Medicare Part D, Medicaid, and multiple time periods. Strong for pattern identification but cannot establish individual-level causation.
When this study was published
Published 2016, data 2010-2013. Follow-up studies through 2018 confirmed and extended the findings.
The bigger picture
Demonstrates that cannabis legalization affects the entire pharmaceutical landscape — not just opioids. The economic argument for legalization extends beyond tax revenue to reduced healthcare spending.
Questions still open
- Do patients who substitute cannabis for prescriptions have better or worse outcomes? Is the substitution pattern sustained long-term? Which patients benefit most from substitution?
Common questions
Read the original research
Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D.
Health Affairs, 35(7), 1230-1236
Citation
Bradford, Ashley C; Bradford, W David. (2016). Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D.. Health Affairs, 35(7), 1230-1236. https://doi.org/10.1377/hlthaff.2015.1661